Triple Negative Breast Cancer (TNBC) – defined as estrogen receptor, progesterone receptor and human epidermal growth factor receptor type 2 (HER2) negativity – is heterogeneous with respect to biology, prognosis and response to treatment. TNBC is associated with younger age at diagnosis and with poorer outcomes compared with non-TNBC. Studies to enhance our understanding of TNBC are needed to improve our understanding of its biology and current management and outcome of patients diagnosed with TNBC.
This funding opportunity was made available through a generous philanthropic donation to the UF Health Cancer Center by the Collaboration of Scientists for Critical Research in Biomedicine (CSCRB, Inc.). It recognizes that i) the study of TNBC is underrepresented in academic and industry research portfolios, and ii) there exists a great need to advance our understanding of the genetics and biology of TNBC and for implementing new strategies for clinical trials.
The goals of the TNBC Research Grant are to:
- Identify new research opportunities focused on the biology or treatment of TNBC;
- Create synergies and collaborations within UF Health Cancer Center, the University of Florida, and, if applicable, Orlando Health, UFPTI or other institutions;
- Stimulate applications for future program-type federal or national extramural funding
The deadline for receipt of applications is: November 17, 2014.